Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,576 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database.
Kawai M, Takada M, Nakayama T, Masuda N, Shiheido H, Cai Z, Huang YJ, Kawaguchi T, Tanizawa Y. Kawai M, et al. Among authors: kawaguchi t. Breast Cancer Res Treat. 2023 Jan;197(2):435-447. doi: 10.1007/s10549-022-06816-9. Epub 2022 Nov 21. Breast Cancer Res Treat. 2023. PMID: 36414795 Free PMC article.
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Inoue K, Masuda N, Iwata H, Takahashi M, Ito Y, Miyoshi Y, Nakayama T, Mukai H, van der Walt JS, Mori J, Sakaguchi S, Kawaguchi T, Tanizawa Y, Llombart-Cussac A, Sledge GW Jr, Toi M. Inoue K, et al. Among authors: kawaguchi t. Breast Cancer. 2021 Sep;28(5):1038-1050. doi: 10.1007/s12282-021-01239-8. Epub 2021 Apr 1. Breast Cancer. 2021. PMID: 33797023 Free PMC article. Clinical Trial.
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Takahashi M, Tokunaga E, Mori J, Tanizawa Y, van der Walt JS, Kawaguchi T, Goetz MP, Toi M. Takahashi M, et al. Among authors: kawaguchi t. Breast Cancer. 2022 Jan;29(1):174-184. doi: 10.1007/s12282-021-01295-0. Epub 2021 Oct 18. Breast Cancer. 2022. PMID: 34661821 Free PMC article. Clinical Trial.
Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.
Masuda N, Chen Y, Kawaguchi T, Dozono K, Toi M. Masuda N, et al. Among authors: kawaguchi t. Cancer Manag Res. 2022 Mar 19;14:1179-1194. doi: 10.2147/CMAR.S348591. eCollection 2022. Cancer Manag Res. 2022. PMID: 35342308 Free PMC article.
Risk factors for recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer in Japan: a systematic literature review and meta-analysis.
Miyazaki N, Iwasaki T, Sakai H, Watanuki R, Tanizawa Y, Cai Z, Kawaguchi T, Tsurutani J, Nagashima K. Miyazaki N, et al. Among authors: kawaguchi t. Curr Med Res Opin. 2024 May;40(5):827-837. doi: 10.1080/03007995.2024.2332436. Epub 2024 Apr 10. Curr Med Res Opin. 2024. PMID: 38597173 Review.
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
Hattori M, Serelli-Lee V, Naito Y, Yamanaka T, Yasojima H, Nakamura R, Fujisawa T, Imai M, Nakamura Y, Bando H, Kawaguchi T, Yoshino T, Iwata H. Hattori M, et al. Among authors: kawaguchi t. JCO Precis Oncol. 2024 Apr;8:e2300647. doi: 10.1200/PO.23.00647. JCO Precis Oncol. 2024. PMID: 38635933
2,576 results